Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2024-04-02 AGM Information
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Notice of annual general meeting in Xbrane Biopharma AB
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of annual general meeting in Xbrane Biopharma AB" and details the date, location, procedures for attendance, and the proposed agenda for this meeting. The agenda items cover standard AGM business such as electing the chairman, approving the agenda, presenting annual reports, resolutions on profit distribution, determining director/auditor fees, electing directors/auditors, and approving incentive programs and remuneration reports. This content is characteristic of materials distributed to shareholders in preparation for an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2024-04-02 English
Kallelse till årsstämma i Xbrane Biopharma AB
AGM Information Classification · 99% confidence The document is titled "Kallelse till årsstämma i Xbrane Biopharma AB" (Notice of Annual General Meeting in Xbrane Biopharma AB). It details the date, time, location, registration procedures, and the proposed agenda for the meeting. The agenda includes items typical for an AGM, such as electing the chairman, approving the annual report (Item 6), deciding on profit distribution (Item 7b), electing the board and auditors (Items 8-10), and approving incentive programs (Item 11). The presence of a formal 'Kallelse' (Notice) and a detailed agenda for the 'årsstämma' (Annual General Meeting) strongly indicates this document is related to the AGM. While it contains proposals that might appear in a Proxy Statement (DEF 14A/PSI), the primary function of this specific document is to formally convene the meeting. In the provided definitions, 'AGM Information' (AGM-R) covers presentations and materials shared during the AGM. A formal notice of the AGM is a core material for that event. It is not the Annual Report (10-K), nor is it purely a Proxy Solicitation (PSI), although it contains elements that would be included in one. Given the explicit reference to the 'årsstämma' and the nature of the content (the official call/notice), AGM-R is the most appropriate classification.
2024-04-02 Swedish
Change of number of shares and votes in Xbrane
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces a 'Change of number of shares and votes in Xbrane' resulting from previously resolved rights issues and directed issues. It provides the new total number of shares and the registered share capital as of a specific date (31 March 2024). This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the core content is the capital change itself, not just an announcement of a separate report, making SHA a better fit than RPA or RNS. The final line confirms it is regulatory information, but SHA is the most specific category.
2024-04-01 English
Förändrat antal aktier och röster i Xbrane
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text explicitly states that Xbrane Biopharma AB has completed a rights issue and a directed issue, resulting in a change to the total number of shares and votes. It provides the new total share count as of March 31, 2024. This content directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). The document is short and appears to be an official announcement regarding this change, not a comprehensive report.
2024-04-01 Swedish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage by Nordnet AB (publ), specifically noting a 'Sell' transaction and providing the resulting share quantity and percentage (4.72205%). This structure, focusing on the notification of a change in significant share ownership, directly aligns with the definition of a Major Shareholding Notification. The code for this is MRQ.
2024-03-28 English
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-03-27 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.